Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

AACR news: squalamine evaluated for activity in prostate and lung cancer models

April 20, 1999

Potent and long-lasting GnRH antagonist presented by Ferring

April 20, 1999

FDA grants priority review status to Alza' sNDA for Doxil in ovarian cancer

April 20, 1999

SBR-170: a new bioreductive alkylating agent selected for further evaluation

April 20, 1999

BNP-7787 protects against taxane- and platinum-associated neurotoxicity

April 20, 1999

Further phase I data presented for bizelesin at AACR meeting

April 20, 1999

Structural Bioinformatics awarded SBIR grant for HER2 antagonists

April 20, 1999

News from AACR: 9-NC does not require conversion to 9-AC to exert antitumor activity

April 19, 1999

NX-211 compared to free lurtotecan regarding pharmacokinetics, toxicity and efficacy

April 19, 1999

CD-437: new apoptogenic retinoid examined for resistance using leukemia cells

April 19, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.